982 1030
are encouraged to participate in clinical trials, one major
bottleneck is the lack of trials willing to accept RKC patients.
Even trials specifically aimed at RCCs will exclude the vast
majority RKCs. It is of utmost importance to communicate
the need for these studies to pharmaceutical companies and
academic centers.
Author contributions:
Rachel H. Giles had full access to all the data in the
study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design:
None.
Acquisition of data:
None.
Analysis and interpretation of data:
None.
Drafting of the manuscript:
Giles, Bex.
Critical revision of the manuscript for important intellectual content:
Choueiri, Heng, Albiges, Hsieh, Linehan, Pal, Maskens, Paseman, Jonasch,
Malouf, Molina, Pickering, Shuch, Srinivas, Srinivasan, Tannir.
Statistical analysis:
None.
Obtaining funding:
None.
Administrative, technical, or material support:
None.
Supervision:
None.
Other:
None.
Financial disclosures:
Rachel H. Giles certifies that all conflicts of interest,
including specific financial interests and relationships and affiliations
relevant to the subject matter or materials discussed in the manuscript
(eg, employment/affiliation, grants or funding, consultancies, honoraria,
stock ownership or options, expert testimony, royalties, or patents filed,
received, or pending), are the following: Rachel Giles and Deborah
Maskens: IKCC receives funding from BMS, Eisai, Pfizer Oncology,
Novartis, Exelixis, Ipsen, Merck MSD. Toni Choueiri: consulting or
advisory board: AstraZeneca, Bayer, BMS, Cerulean, Eisai, Foundation
Medicine Inc., Genentech, GlaxoSmithKline, Merck, Novartis, Peloton,
Pfizer, Prometheus Labs Inc, Roche, Eisai; research funding: AstraZeneca,
BMS, Exelixis, Genentech, GSK, Merck, Novartis, Peloton, Pfizer, Roche,
Tracon, Eisai. Laurence Albiges: receipt of honoraria or consultation fees
fromNovartis, Pfizer, BMS. Eric Jonasch: research funding: Exelixis, Pfizer,
Novartis; honoraria: BMS, Eisai, Exelixis, Novartis, Pfizer. Gabriel Malouf:
research funding: Novartis, Pfizer; consulting: Novartis, Pfizer, BMS,
Janssen. Ana Molina: consulting fees from Novartis, Exelixis and EISAI.
Marston Linehan: none. Lisa Pickering: consultancies and/or honoraria:
BMS, Ipsen, MSD, Novartis, Pfizer. Brian Shuch: none. Nizar Tannir: travel/
honoraria and consulting: BMS, Exelixis, Nektar, Novartis, Pfizer, Argos,
Calithera; research: BMS, Exelixis, Epizyme, Novartis, Miranti. James
Hsieh: consultant for Pfizer, Eisai, Chugai; receipt of research funding
from Pfizer, Novartis, Eisai, Cancer Genomics Inc. Axel Bex: consultant for
Pfizer, Novartis, Ipsen; honorarium from Pfizer; Trial participation with
Roche, BMS; receipt of grants/research support: Pfizer.
Funding/Support and role of the sponsor:
James J. Hsieh is sponsored by
the Tuttle Family Rare Kidney Cancer Fund.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/j. eururo.2017.06.040 .References
[1]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.[2]
Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. Eur Urol 2016;70:93–105.[3]
Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913–24.[4]
Fernandez-Pello S, Hofmann F, Tahbaz R, et al. A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carci- noma. Eur Urol 2017;71:426–36.[5]
MacLennan SJ, MacLennan S, Bex A, et al. Changing current practice in urology: improving guideline development and implementation through stakeholder engagement. Eur Urol 2017;72:161–3.[6]
Leung C, Pan S, Shuch B. Management of renal cell carcinoma in young patients and patients with hereditary syndromes. Curr Opin Urol 2016;26:396–404.
[7]
Shuch B, Vourganti S, Ricketts CJ, et al. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol 2014;32:431–7.[8]
Kassouf W, Sanchez-Ortiz R, Tamboli P, et al. Cytoreductive ne- phrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol 2007;178:1896–900.
[9]
Kroeger N, Xie W, Lee JL, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013;119:2999–3006.[10]
Vera-Badillo FE, Templeton AJ, Duran I, et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta- analysis. Eur Urol 2015;67:740–9.[11]
Escudier B, Molinie V, Bracarda S, et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary met- astatic renal cell carcinoma: RAPTOR final analysis. Eur J Cancer 2016;69:226–35.
[12]
Tannir NM, Jonasch E, Albiges L, et al. Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–clear Cell Renal Cell Carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol 2016;60:866–74.
[13]
Armstrong AJ, Halabi S, Eisen T, et al. Everolimus Versus Sunitinib for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lan- cet Oncol 2016;17:378–88.[14]
Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line suniti- nib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 2014;32:2765–72.
[15]
Ravaud A, Oudard S, De Fromont M, et al. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG) dagger. Ann Oncol 2015; 26:1123–8.
[16]
Nielsen SM, Rhodes L, Blanco I, et al. Von Hippel–Lindau disease: genetics and role of genetic counseling in a multiple neoplasia syndrome. J Clin Oncol 2016;34:2172–81.
[17]
Linehan WM, Spellman PT, Ricketts CJ, et al. Comprehensive mo- lecular characterization of papillary renal-cell carcinoma. N Engl J Med 2016;374:135–45.
[18]
Durinck S, Stawiski EW, Pavia-Jimenez A, et al. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma sub- types. Nat Genet 2015;47:13–21.
[19]
Chen F, Zhang Y, Senbabaoglu Y, et al. Multilevel genomics-based taxonomy of renal cell carcinoma. Cell Rep 2016;14:2476–89.
[20]
Joshi S, Tolkunov D, Aviv H, et al. The genomic landscape of renal oncocytoma identifies a metabolic barrier to tumorigenesis. Cell Rep 2015;13:1895–908.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 9 7 4 – 9 8 3
982